SCHEMBL26031939

SCHEMBL26031939

CCCCCCCCCCCCCCCC(=O)NCCCOCCNC(=O)CC[C@H](NC(=O)CC(C)C)C(=O)NCCCOCCCNC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC[C@H]([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@@H]32)C1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ POLA1 P09884 1/20 0.52
▸ CYP46A1 Q9Y6A2 2/20 0.51
▸ PLA2G2A P14555 1/20 0.48
▸ USP2 O75604 2/20 0.47
▸ LMNA P02545 1/20 0.47
▸ ABCB1 P08183 1/20 0.47
▸ OSBP P22059 1/20 0.47
▸ RORC P51449 1/20 0.47
▸ OSBP2 Q969R2 1/20 0.47
▸ EPHA2 P29317 2/20 0.46
▸ GBA1 P04062 2/20 0.46
▸ UGCG Q16739 2/20 0.46
▸ GBA2 Q9HCG7 2/20 0.46
▸ NR1H3 Q13133 2/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ NPC1L1 Q9UHC9 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26031942 0.96 POLA1 (0.52) POLA1CYP46A1PLA2G2AUSP2LMNA
SCHEMBL25835535 0.90 POLA1 (0.55) POLA1CYP46A1PLA2G2AUSP2LMNA
SCHEMBL15160238 0.89 POLA1 (0.60) POLA1CYP46A1PLA2G2AUSP2LMNA
SCHEMBL25839904 0.89 POLA1 (0.48) POLA1CYP46A1PLA2G2AUSP2LMNA
SCHEMBL26032901 0.89 POLA1 (0.54) POLA1CYP46A1PLA2G2AUSP2LMNA
SCHEMBL15160094 0.88 POLA1 (0.60) POLA1CYP46A1PLA2G2AUSP2LMNA
SCHEMBL26032057 0.88 POLA1 (0.44) POLA1CYP46A1PLA2G2AUSP2LMNA
SCHEMBL25836050 0.88 POLA1 (0.46) POLA1CYP46A1PLA2G2AUSP2LMNA
SCHEMBL25835539 0.87 POLA1 (0.47) POLA1CYP46A1PLA2G2AUSP2LMNA
SCHEMBL26032034 0.87 POLA1 (0.46) POLA1CYP46A1PLA2G2AUSP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF MUSK, MYLK2, TNNC1 POLA1 2871/4885CYP46A1 4314/4885PLA2G2A 1323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback